Baseline SII and SIRI identify immune-inflammatory susceptibility and improve risk stratification of early subclinical cardiac dysfunction during non-steroidal aromatase inhibitor therapy.
Li C, Tao Z, Wu Y, Wu C, Wang Z, Wang X, Dai H, Jiang M, Pu J
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.